SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference
JERSEY CITY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental Boston on Thursday, August 11, 2016 at 2:00 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 hsavelle@macbiocom.com Investor Relations Susan Kim Argot Partners Tel: 212.203.4433 susan@argotpartners.com
Released August 4, 2016